GSK Exits $4.2bn Cancer Drug Deal With Merck KGaA After Multiple Failures

Plug Pulled After Three Trial Flops

 
• By Andrew McConaghie
  
GSK Exit
GSK is exiting the deal after paying an upfront fee of $360m, but will not have to pay any milestones after bintrafusp's disappointing results.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip